

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**(Use as many sheets as necessary)**

Sheet	1	of	4
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	<b>10/559,647</b>
<b>Filing Date</b>	<b>07/31/2006</b>
<b>First Named Inventor</b>	<b>Rosanne M. Crooke</b>
<b>Art Unit</b>	<b>1635</b>
<b>Examiner Name</b>	<b>Amy Hudson Bowman</b>
<b>Attorney Docket Number</b>	<b>ISPH-0595USA</b>

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

/Amy Bowman/

Date Considered

05/08/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

**Complete if Known**

Application Number	10/559,647
Filing Date	07/31/2006
First Named Inventor	Rosanne M. Crooke
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	ISPH-0595USA

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AB/	AQ	AGRAWAL, S., "Antisense oligonucleotides: towards clinical trials," <i>TIBTECH</i> (1996) 14:376-387.	
	AR	ANDERSON, L. et al., "A comparison of selected mRNA and protein abundances in human liver," <i>Electrophoresis</i> (1997) 18:533-537.	
	AS	BRAASCH, D. A. et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochem.</i> (2002) 41(14):4503-4510.	
	AT	BRANCH, A. D., "A good antisense molecule is hard to find," <i>TIBS</i> (1998) 23:45-50.	
	AU	CALLOW, M. J. et al., "Expression of human apolipoprotein B and assembly of lipoprotein (a) in transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> (1994) 91:2130-2134.	
	AV	CHIESA, G. et al., "Reconstitution of Lipoprotein (a) by Infusion of Human Low Density Lipoprotein into Transgenic Mice Expressing Human Apolipoprotein (a)," <i>J. Biol. Chem.</i> (1992) 267(34):24369-24374.	
	AW	CHIN, A., "On Preparation and Utilization of Isolated and Purified Oligonucleotides," Katherine R. Everett Law Library of the University of North Carolina, March 14, 2002.	
	AX	DEVERRE, J.-R. et al., "A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides," <i>Nucleic Acids Res.</i> (1997) 25(18):3584-3589.	
	AY	DIAS, N. et al., "Potential roles of antisense oligonucleotides in cancer therapy. The example of bcl-2 antisense oligonucleotides," <i>Eur. J. Pharm. Biopharm.</i> (2002) 54:263-269.	
	AZ	FRANK, S. et al., "Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo," <i>Gene Therapy</i> (2001) 8:425-430.	
	BA	FRANK, S. et al., "The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen," <i>Hum. Genet.</i> (1988) 79(4):352-356.	
	BB	FRITZ, H. et al., "Cationic Polystyrene Nanoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides," <i>J. Colloid Interface Sci.</i> (1997) 195:272-288.	
✓	BC	GEWIRTZ, A. M. et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise," <i>Proc. Natl. Acad. Sci. USA</i> (1996) 93:3161-3163.	

Examiner Signature	/Amy Bowman/	Date Considered	05/08/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 4

**Complete if Known**

Application Number	10/559,647
Filing Date	07/31/2006
First Named Inventor	Rosanne M. Crooke
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	ISPH-0595USA

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AB/	BD	GRAINGER, D. J. et al., "Activation of transforming growth factor- $\beta$ is inhibited in transgenic apolipoprotein(a) mice," <i>Nature</i> (1994) 370:460-462.	
	BE	GREEN, D. W. et al., "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease," <i>J. Am. Coll. Surg.</i> (2000) 191:93-105.	
	BF	HAJJAR, K. A. et al., "The Role of Lipoprotein(a) in Atherogenesis and Thrombosis," <i>Annu. Rev. Med.</i> (1996) 47:423-442.	
	BG	JEN, K.-Y. et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> (2000) 18:307-319.	
	BH	KATAN, M. B. et al., "Characteristics of Human Hypo- and Hyperresponders to Dietary Cholesterol," <i>Am. J. Epidemiology</i> (1987) 125(3):387-399.	
	BI	KOSTNER, K. M. et al., "Lipoprotein(a): still an enigma?" <i>Current Opinion in Lipidology</i> (2002) 13:391-396.	
	BJ	LAWN, R. M. et al., "Atherogenesis in transgenic mice expressing human apolipoprotein(a)," <i>Nature</i> (1992) 360:670-672.	
	BK	MCLEAN, J. W. et al., "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen," <i>Nature</i> (1987) 330:132-137.	
	BL	MILLIGAN, J. F. et al., "Current Concepts in Antisense Drug Design," <i>J. Med. Chem.</i> (1993) 36(14):1923-1927.	
	BM	MORISHITA, R. et al., "Novel Therapeutic Strategy for Atherosclerosis - Ribozyme Oligonucleotides Against Apolipoprotein(a) Selectively Inhibit Apolipoprotein(a) But Not Plasminogen Gene Expression," <i>Circulation</i> (1998) 98:1898-1904.	
	BN	NOWAK-GÖTTL, U. et al., "Lipoprotein (a): Its Role in Childhood Thromboembolism," <i>Pediatrics</i> (1997) 99(6):1-3.	
	BO	OHMACHI, T. et al., "The virtues of self-binding: high sequence specificity for RNA cleavage by self-processed hammerhead ribozymes," <i>Nucleic Acids Res.</i> (2000) 28(3):776-783.	
↓	BP	OPALINSKA, J. B. et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Reviews Drug Discovery</i> (2002) 1:503-514.	

Examiner Signature	/Amy Bowman/	Date Considered	05/08/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 4

**Complete If Known**

Application Number	10/559,647
Filing Date	07/31/2006
First Named Inventor	Rosanne M. Crooke
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	ISPH-0595USA

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AB/	BQ	PROSNYAK, M. I. et al., "Substitution of 2-Aminoadenine and 5-Methylcytosine for Adenine and Cytosine in Hybridization Probes Increases the Sensitivity of DNA Fingerprinting," <i>Genomics</i> (1994) 21:490-494.	
	BR	RAINWATER, D. L. et al., "Lipoprotein Lp(a): Effects of Allelic Variation at the <i>LPA</i> Locus," <i>J. Exp. Zoology</i> (1998) 282:54-61.	
	BS	SANDKAMP, M. et al., "Lipoprotein(a) is an Independent Risk Factor for Myocardial Infarction at a Young Age," <i>Clin. Chem.</i> (1990) 36(1):20-23.	
	BT	SEED, M. et al., "Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia," <i>New Engl. J. Med.</i> (1990) 322:1494-1499.	
	BU	SKERRA, A., "Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerase with proofreading activity," <i>Nucleic Acids Res.</i> (1992) 20(14):3551-3554.	
	BV	TAMM, I. et al., "Antisense therapy in oncology: new hope for an old idea?" <i>The Lancet</i> (2001) 358:489-497.	
	BW	VESSBY, B. et al., "Diverging Effects of Cholestyramine on Apolipoprotein B and Lipoprotein Lp(a)," <i>Atherosclerosis</i> (1982) 44:61-71.	
	BX	WEINTRAUB, H. M., "Antisense RNA and DNA," <i>Scientific American</i> (1990) 40-46.	
↓	BY	YANG, Y. et al., "Transforming Growth Factor-β1 Inhibits Human Keratinocyte Proliferation by Upregulation of a Receptor-Type Tyrosine Phosphatase R-PTP-κ Gene Expression," <i>Biochem. Biophys. Res. Commun.</i> (1996) 228:807-812.	

Examiner Signature	/Amy Bowman/	Date Considered	05/08/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.